Sagent Pharmaceuticals has appointed Michael Fekete as the sixth member of its board of directors.
Fekete is currently director at both pharma firm DFB Pharmaceuticals and Symetis SA, which creates minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases.
He is a corporate adviser specialising in capital markets, mergers and acquisitions and general corporate strategy and has experience at Oppenheimer & Co and L F Rothschild & Co.
Illinois, US-based injectable specialist Sagent will benefit from his advice as it looks to expand following its successful initial public offering, which Fekete assisted in an advisory role.
“Mike’s experience and skill set will be particularly valuable to us as we continue to drive our growth,” said Jeffrey Yordon, founder, CEO and chairman of the board of Sagent.
“We look forward to his contribution to the board of directors and his involvement with senior management of the company.”